Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Positive Results for Anti-Obesity Drug Oxyntomodulin

By Drug Discovery Trends Editor | June 6, 2011

 Prolor Biotech, Inc. reported positive results from a comparative animal study of its anti-obesity drug candidate oxyntomodulin (OXY-RPEG).

The study measured the potential therapeutic effect of OXY-RPEG injected once or twice weekly as measured by weight loss and reduction in food intake compared with being injected twice daily.

It was conducted using an animal model specifically designed to test anti-obesity drugs. In the study, OXY-RPEG injected either once or twice over a period of seven days demonstrated significantly higher weight loss, reduction of food intake and duration of weight loss activity compared with being injected twice daily.
 
Oxyntomodulin is a naturally occurring peptide hormone released by the digestive system that acts as a natural satiety signal to reduce food intake and increase energy expenditure following food ingestion. Previous studies in humans showed that oxyntomodulin can reduce appetite and food intake, leading to significant weight loss without apparent side effects.

 However, as a result of oxyntomodulin’s very short half-life, it had to be administered via three daily injections in these human studies. Prolor developed its longer-acting OXY-RPEG version by combining a naturally occurring oxyntomodulin with the company’s proprietary Reversible PEGylation technology designed to increase the half-life of therapeutic peptides and small molecules.
 
OXY-RPEG demonstrated greater potency, with the total dose administered over seven days containing approximately 15% of the cumulative dose of oxyntomodulin injected during the same period.

Release Date: June 6, 2011
Source: Prolor Biotech, Inc 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50